Clinical Trials Logo

Sarcomatoid Renal Cell Carcinoma clinical trials

View clinical trials related to Sarcomatoid Renal Cell Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05808608 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Start date: September 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic special pathological subtypes of renal cell carcinoma (ssRCC). Subjects will receive AK104 plus axitinib until disease progression, development of unacceptable toxic effects, death, a decision by the physician or patient to withdraw from the trial. The primary endpoint is ORR and PFS per RECIST v1.1 and imRECIST as assessed by investigators.